Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, octubre 10
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Repligen Corp
RGEN
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$173.88
10.04
6.13%
Últ. Act.: Oct 9, 4:00 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Fusiones y adquisiciones:
BioLife Solutions (BLFS) was acquired by Repligen (RGEN) on Tuesday, October 6, 2026 for $1.5B paid in cash & stock
Repligen Financials
Repligen (RGEN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Repligen Q2 Adj. EPS $0.54 Beats $0.45 Estimate, Sales $204.128M Beat $201.483M Estimate
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.45 by 20 percent. This is a 45.95 percent increase over earnings of $0.37 per share from the same
Benzinga Newsdesk
PRO
Repligen Raises FY2026 Adj EPS Guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 Est; Raises FY2026 Sales Guidance from $803.000M-$833.000M to $813.000M-$835.000M vs $822.537M Est
Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 analyst estimate. Raises FY2026 sales outlook from $803.000 million-$833.000 million to $813.000 million-$835.000 million vs
Benzinga Newsdesk
PRO
Repligen Raises FY2026 Adj EPS Guidance from $1.93-$2.01 to $1.97-$2.05 vs $1.97 Est; Lowers FY2026 Sales Guidance from $810.000M-$840.000M to $803.000M-$833.000M vs $827.641M Est
CURRENT GUIDANCE (at May 5, 2026) FY 2026Adjusted (non-GAAP)Total Reported Revenue$803M - $833MReported Growth9% - 13%Organic Growth9% - 13%Gross Margin53.7% - 54.2%Income from Operations$124M - $132MOperating
Benzinga Newsdesk
PRO
Repligen Raises FY2026 Adj EPS Guidance from $1.93-$2.01 to $1.97-$2.05 vs $1.97 Est
FINANCIAL GUIDANCE FOR FULL YEAR 2026All adjusted figures are non-GAAPOur financial guidance for the full year 2026 is based on expectations for our existing business. Our Adjusted (non-GAAP) guidance excludes the
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
PRO
Repligen Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $194.255M Beat $192.279M Estimate
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.39 by 23.08 percent. This is a 23.08 percent increase over earnings of $0.39 per share from the same
Benzinga Newsdesk
